Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include MarketBeat, finance.yahoo.com, STAT and Fierce Biotech. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 75d ago.
Quick answers
Why is "Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipel" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (13)
- RARE Stock Heads For Record Low: Angelman Trial Miss Leads To Wall Street Downgrades Yahoo Finance · 75d ago
- Ultragenyx vows 'significant' cuts after experimental rare-disease drug flunks late-stage clinical trial The Business Journals · 75d ago
- Why Did RARE Stock Slump 46% After-Hours? Yahoo Finance · 75d ago
- Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial STAT · 75d ago
- Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study BioPharma Dive · 75d ago
- Ultragenyx to slash costs after Angelman trial failure pharmaphorum · 75d ago
- Ultragenyx mulls fate of rare disease programme on Phase III flop Clinical Trials Arena · 75d ago
- Ultragenyx Pharmaceutical (NASDAQ:RARE) Rating Lowered to "Equal Weight" at Wells Fargo & Company MarketBeat · 75d ago
- Ultragenyx Shares Fall After Phase 3 Aspire Study Misses Primary Endpoint finance.yahoo.com · 75d ago
- We’re reading about an Ultragenyx failure, RevMed for lung cancer, and more STAT · 75d ago
- Ultragenyx fails phase 3 Angelman test, plots ‘significant expense reductions’ Fierce Biotech · 75d ago
- Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline Barron's · 75d ago
- Ultragenyx's ASO fails in Angelman syndrome, triggering sell-off FirstWord PHARMA · 75d ago
Topics
Related trends
Trump Backs Jensen Huang After Nvidia CEO Confirmed His Affair
President Donald Trump suggested Tim Cook should replace Jensen Huang as Nvidia CEO following Huang's resignation.
Stock futures rise slightly as investors eye AI trade, brace for more data and earnings: Live updates
Stock futures rallied as investors bought the dip following a volatile week, though Nvidia shares dropped premarket.
Bloom Energy Stock Rallies as Barclays Turns Bullish on California Power Partnership
Bloom Energy stock rallies following a strategic California power partnership and a bullish shift by Barclays.
Berkshire After Buffett: Steady Hands, Big Bets In The Greg Abel Era
Market analysts focus on Greg Abel's upcoming 13F filing and portfolio strategy at Berkshire Hathaway.
After the US midterm rout of Trumpism, the world struggles to trust America again
Democrats won control of both houses of Congress in a midterm rout of Trumpism, but global leaders and citizens say one election does not restore trust in America.
Amazon and Google Could Own $400 Billion of Anthropic Stock
Recent financial reporting highlights a massive potential valuation for Amazon and Google holdings in Anthropic stock.